
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) rose sharply in pre-market trading after the company disclosed that the FDA has lifted the clinical hold on the pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease.
Rocket Pharmaceuticals shares jumped 15.8% to $3.37 in the pre-market trading session.